Eli Lilly Acquires POINT Biopharma Global

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Biotechnology

Bristol Myers Squibb agreed to acquire clinical-stage precision oncology company Turning Point Therapeutics in an all-cash transaction valuing the company at approximately $4.1 billion ($76.00 per share). The deal adds Turning Point's lead asset, repotrectinib, and its precision oncology pipeline to BMS's oncology franchise and is expected to close in 2022 (tender offer completed and merger subsequently closed).

Eli Lilly Acquires Sigilon Therapeutics

June 29, 2023

Biotechnology

Eli Lilly agreed to acquire Sigilon Therapeutics in a cash tender offer valuing the biotech at roughly $34.6 million up front plus contingent value rights that could increase total consideration to about $309.6 million. The acquisition brings Sigilon's encapsulated cell therapy platform (including SIG-002 for type 1 diabetes) into Lilly's diabetes and cell-therapy R&D efforts to accelerate development and potential commercialization.

Eli Lilly Acquires DICE Therapeutics

June 20, 2023

Biotechnology

Eli Lilly agreed to acquire DICE Therapeutics for $48 per share (approximately $2.4 billion) in an all-cash tender offer to bolster Lilly's immunology pipeline and leverage DICE's DELSCAPE small-molecule discovery platform and oral IL-17 inhibitor programs. The transaction, approved by both boards, is expected to close in Q3 2023 subject to customary conditions and antitrust clearance.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.

Galapagos NV Acquires CellPoint and AboundBio

June 21, 2022

Biotechnology

Galapagos NV has acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies, combining CellPoint's decentralized point-of-care CAR-T manufacturing platform with AboundBio's fully human antibody discovery capabilities. The deal includes an upfront €125 million for CellPoint (plus up to €100 million in milestones) and $14 million for AboundBio, positioning Galapagos to expand its cell therapy pipeline and validate a rapid vein-to-vein delivery model.

RxVantage Acquires onPoint Oncology

November 10, 2020

Healthcare Services

RxVantage has acquired onPoint Oncology, a provider of oncology reimbursement data and analytics, with onPoint operating as a wholly owned subsidiary. The acquisition integrates onPoint's revenue-cycle data and reimbursement insights into RxVantage's digital platform to expand capabilities for oncology practices and life science customers.